International Journal of Infectious Diseases
Volume 14, Issue 1 , Pages e28-e33 , January 2010

HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran

  • Afarin Rahimi-Movaghar

      Affiliations

    • Iranian Research Center for HIV/AIDS (IRCHA), Tehran University of Medical Sciences, Imam Khomeini Hospital, Keshavarz Blvd., Tehran, Iran
    • ,
  • Emran M. Razaghi

      Affiliations

    • Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, 669 South Kargar Avenue, Tehran 13366-16357, Iran
    • ,
  • Elaheh Sahimi-Izadian

      Affiliations

    • Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, 669 South Kargar Avenue, Tehran 13366-16357, Iran
    • ,
  • Masoumeh Amin-Esmaeili

      Affiliations

    • Iranian Research Center for HIV/AIDS (IRCHA), Tehran University of Medical Sciences, Imam Khomeini Hospital, Keshavarz Blvd., Tehran, Iran
    • Corresponding Author InformationCorresponding author. Tel.: +98 21 66947984; fax: +98 21 66947984.

Received 7 October 2008 ,Revised 18 February 2009 ,Accepted 1 March 2009.

References 

  1. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372:1733–1745
  2. Rahimi-Movaghar A, Mohammad K, Razzaghi EM. Trend of drug abuse in Iran: a three decade analysis [in Persian]. Hakim Res J. 2002;5:171–182
  3. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol. 2008;48:353–367
  4. Pallás JR, Fariñas-Álvarez C, Prieto D, Delgado-Rodríguez M. Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur J Epidemiol. 1999;15:699–704
  5. Hernandez-Aguado I, Ramos-Rincon JM, Avinio MJ, Gonzalez-Aracil J, Perez-Hoyos S, de la Hera MG. Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users. Eur J Epidemiol. 2001;17:539–544
  6. National AIDS Committee, Ministry of Health. Iran Country report on monitoring of the United Nations general assembly special session on HIV and AIDS, declaration of commitment [in Persian]. Tehran: Iranian Ministry of Health; 2008, p. 19–21.
  7. Alavian SM, Adibi P, Zali MA. Hepatitis C virus in Iran: epidemiology of an emerging infection. Arch Iranian Med. 2005;8:84–90
  8. Forouzanfar MH, Mohammad K, Majdzadeh R, Malekzadeh R, Abolhasani F, Mohammadnejad M, et al. Effectiveness of adolescent immunization against hepatitis B on burden of the disease in Iran [in Persian]. Hakim Res J. 2006;9:1–11
  9. Razzaghi EM, Rahimi-Movaghar A, Green TC, Khoshnood K. Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J. 2006;3:12
  10. Bureau for Psychosocial Health, Iranian Ministry of Health. National report on drug abuse services, 2007. Tehran: Iranian Ministry of Health; 2008.
  11. Hagan H, Thiede H, Des Jarlais DC. HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention. AIDS. 2005;19(Suppl 3):S199–207
  12. Zamani S, Kihara M, Gouya MM, Vazirian M, Nassirimanesh B, Ono-Kihara M, et al. High prevalence of HIV infection associated with incarceration among community-based injecting drug users in Tehran. Iran. J Acquir Immune Defic Syndr. 2006;42:342–346
  13. Khamisipour GR, Tahmasebi R. Prevalence of HIV, HBV, HCV and syphilis infection in high risk groups of Bushehr Province, 1999 [in Persian]. Iranian South Med J. 2000;3:53–59
  14. Mohtasham Amiri Z, Rezvani M, Jafari Shakib R, Jafari Shakib A. Prevalence of hepatitis C virus infection and risk factors of drug using prisoners in Guilan Province. East Mediterr Health J. 2007;13:250–256
  15. Khodadadi-Zadeh A, Esmaeili Nadimi A, Hosseini SH, Shabani Shahrbabaki Z. The prevalence of HIV, HBV and HCV in narcotic addicted persons referred to the outpatient clinic of Rafsanjan University of Medical Sciences in 2003 [in Persian]. J Rafsanjan Univ Med Sci. 2006;5:23–30
  16. Mirahmadizadeh AR, Kadivar MR, Ghane Shirazi R, Fararooei M. Prevalence of HIV infection among intravenous drug addicts in Shiraz [in Persian]. J Gorgan Univ Med Sci. 2001;3:39–41
  17. Mir-Nasseri MM, Poustchi H, Nasseri-Moghadam S, Nouraie SM, Tahaghoghi S, Afshar P, et al. HCV in intravenous drug users [in Persian]. Govaresh. 2005;2:80–86
  18. Mohammad-Alizadeh AH, Alavian AM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan – Iran. World J Gastroenterol. 2005;11:4058–4089
  19. Rowhani Rahbar A, Rooholamini S, Khoshnood K. Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. Int J Drug Policy. 2004;15:151–155
  20. Salehi M, Sanei Moghaddam E, Ansari Moghaddam AR. HBsAg and hepatitis C infection prevalence in prisoners of Sistan and Balouchestan Province [in Persian]. Tabibe Shargh. 2001;4:203–206
  21. Zali MR, Aghazadeh R, Nowroozi A, Amir-Rasouly H. Anti-HCV antibody among Iranian IV drug users: is it a serious problem?. Arch Iranian Med. 2001;4:115–119
  22. Amini S, Mahmoodabadi A, Lamian S, Joulaie M, Mahmoodi Farahani M. Prevalence of hepatitis G virus (HGV) in high-risk groups and blood donors in Tehran. Iran. Iranian J Public Health. 2005;34:41–46
  23. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy. 2007;18:359–363
  24. Zamani S, Kihara M, Gouya MM, Vazirian M, Ono-Kihara M, Razzaghi EM, et al. Prevalence of and factors associated with HIV-1 infection among drug users visiting treatment centers in Tehran, Iran. AIDS. 2005;19:709–716
  25. Center for Disease Management, Ministry of Health. Current statistics on HIV/AIDS infection in the Islamic Republic of Iran [in Persian]. Tehran: Iranian Ministry of Health; 2007, p. 6.
  26. Vassilev ZP, Hagan H, Lyubenova A, Tomov N, Vasilev G, Krasteva D, et al. Needle exchange use, sexual risk behaviour, and the prevalence of HIV, hepatitis B virus, and hepatitis C virus infections among Bulgarian injection drug users. Int J STD AIDS. 2006;17:621–626
  27. Karimi A. Seroprevalence of HBV, HCV and HIV among intravenous drug users in Iran. J Clin Virol. 2006;36(Suppl 2):210–211
  28. Razzaghi EM, Rahimi-Movaghar A. Rapid assessment and response to injection drug use in Tehran. Tehran: World Health Organization and Iranian Welfare Organization; 2005;
  29. Yao Y, Wang N, Chu J, Ding G, Jin X, Sun Y, et al. Sexual behavior and risks for HIV infection and transmission among male injecting drug users in Yunnan, China. Int J Infect Dis. 2009;13:154–161
  30. Abdala N, Krasnoselskikh TV, Durante AJ, Timofeeva MY, Verevochkin SV, Kozlov AP. Sexually transmitted infections, sexual risk behaviors and the risk of heterosexual spread of HIV among and beyond IDUs in St. Petersburg, Russia. Eur Addict Res. 2008;14:19–25
  31. Zocratto KB, Caiaffa WT, Proietti FA, Carneiro-Proietti AB, Mingoti SA, Ribeiro GJ. HCV and HIV infection and co-infection: injecting drug use and sexual behaviour. AjUDE-Brasil I Project. Cad Saude Publica. 2006;22:839–848
  32. Go VF, Frangakis C, Nam le V, Bergenstrom A, Sripaipan T, Zenilman JM, et al. High HIV sexual risk behaviors and sexually transmitted disease prevalence among injection drug users in Northern Vietnam: implications for a generalized HIV epidemic. J Acquir Immune Defic Syndr. 2006;42:108–115
  33. Altaf A, Shah SA, Zaidi NA, Memon A, Nadeem ur R, Wray N. High risk behaviors of injection drug users registered with harm reduction programme in Karachi, Pakistan. Harm Reduct J. 2007;4:7
  34. Panda S, Saha U, Pahari S, Nathan M, Poddar S, Neogi D, et al. Drug use among the urban poor in Kolkata: behaviour and environment correlates of low HIV infection. Natl Med J India. 2002;15:128–134
  35. Azim T, Bogaerts J, Yirrell DL, Banerjea AC, Sarker MS, Ahmed G, et al. Injecting drug users in Bangladesh: prevalence of syphilis, hepatitis. HIV and HIV subtypes. AIDS. 2002;16:121–123
  36. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis. 2007;7:402–409
  37. Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health. 2008;122:990–1003
  38. Razzaghi EM, Rahimi-Movaghar A, Hosseini M, Madani S, Chatterjee A. Rapid situation assessment of drug abuse in Iran. Tehran: Iranian Welfare Organization and UNDCP; 1999;
  39. Ghanbarzadeh N, Nadjafi Semnani M. A study of HIV and other sexually transmitted infections among female prisoners in Birjand [in Persian]. J Birjand Univ Med Sci. 2006;13:69–75
  40. Jahani MR, Alavian M, Shirzad H, Kabir A, Hajarizadeh B. Distribution and risk factors of hepatitis B, hepatitis C, and HIV infection in a female population with illegal social behaviour. Sex Transm Infect. 2005;81:181–185
  41. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155:645–653

PII: S1201-9712(09)00136-2

doi: 10.1016/j.ijid.2009.03.002

International Journal of Infectious Diseases
Volume 14, Issue 1 , Pages e28-e33 , January 2010

Article Tools

* Image Usage & Resolution